0406 Mineralys series A
BioCentury & Getty Images

Emerging Company Profile

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

Emerging Company Profile: Philadelphia biotech readying Phase II trial of compound it believes is differentiated by selectivity

Philadelphia biotech readying Phase II trial of compound it believes is differentiated by selectivity.

Apr 6, 2021 | 11:50 PM GMT

A VC syndicate led by HBM and Samsara will supply

Read the full 706 word article

How to gain access

Continue reading with a
two-week free trial.